Pharyngitis Treatment Market Trends

Growth Drivers

• Rising healthcare spending: The rising healthcare spending is a prominent driver fueling the growth of the market. The rising spending is enhancing access to modern therapies while also propelling clinical research. The surge in allocation of resources for primary care is also confirming the broader reach. According to data published by the World Economic Forum in 2021, the global spending on health amounted to USD 9.8 trillion, accounting for more than 10.2% of the worldwide GDP. Additionally, budget realignments under CMS's Outpatient Prospective Payment System (OPPS) and Medicaid's extended formulary support have increased prescription volume and enhanced market penetration, particularly in public health institutions.
• Rising cases of pharyngitis and associated infections: The cases of the Group A Streptococcus are increasing as a global burden with rising pollution and allergen exposure. According to data published by the National Institutes of Health in 2022, almost 288.5 million cases of Strep A sore throat occur among children aged 5-14 years. The rising number of patients with infections is ensuring that there will be a consistent necessity for antibiotics and various other supportive drug therapies. These factors are augmenting the market growth during the forecast period.
• Advancements in diagnostic technologies: There has been an increased shift towards the precise and rapid treatments that amalgamate technologies.  Researchers and medical practitioners are emphasizing explicitly distinguishing between bacterial and viral types of pharyngitis, which is imperative to eradicate the misuse of antibiotics. According to the American Medical Association in February 2025, nearly 2/3^rd of medical practitioners are using AI in healthcare services. The surge in utilization of state-of-the-art diagnostic solutions is advancing the diagnostic processes and further acting as a catalyst for the targeted treatments. The application of AI is speeding up the adoption of precision medicine and opening a plenty of opportunities for the market players.

Challenges

• Pediatric formulations reimbursement gaps: The pharyngitis treatment’s pediatric version often seems to be lagging in full reimbursement in several countries. Further, manufacturers are not interested in investing in customized pediatric drug development without any assurance of reimbursement support, slowing down the innovation process and limiting pediatric access to essential care.